Tag: exercise

Exploring the Growing Demand for Safe, At-Home Workouts That Support Strength, Hormonal Balance, and Longevity in Men Over 50

SAN DIEGO, June 26, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (“Cidara”) (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics, today announced the closing of its underwritten public offering of 9,147,727 shares of its common stock, including the exercise in full by the underwriters of their option to purchase an additional 1,193,181 shares, at a price to the public of $44.00 per share. The gross proceeds to Cidara from the offering, before deducting underwriting discounts and commissions and offering expenses, were $402.5 million. All of the shares in the offering were sold by Cidara.

CUPERTINO, Calif., June 26, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced the pricing of its previously announced public offering with existing and new healthcare focused institutional investors for the purchase and sale of 20,000,000 shares of its common stock (or common stock equivalents in lieu thereof) together with Series C warrants to purchase up to 20,000,000 shares of common stock (the "Series C Warrants") and Series D warrants to purchase up to 20,000,000 shares of common stock (the "Series D Warrants"), at a combined offering price of $0.50 per share and accompanying warrants, for aggregate gross proceeds of approximately $10 million before deducting placement agent fees and other offering expenses.

FORM 8.3

FORM 8.3

BEIJING, June 26, 2025 (GLOBE NEWSWIRE) -- Julong Holding Limited (“Julong” or the “Company”) (Nasdaq: JLHL), a growth-oriented provider of intelligent integrated solutions, today announced the pricing of its initial public offering (the “Offering”) of 1,250,000 Class A ordinary shares, par value US$0.0001 per share, at an initial public offering price of US$4.00 per share for a total offering size of approximately US$5.0 million, assuming the underwriter does not exercise its option to purchase additional Class A ordinary shares. The Company’s Class A ordinary shares have been approved for listing on the Nasdaq Capital Market under the ticker symbol “JLHL” and are expected to begin trading on June 26, 2025 Eastern Time. The Offering is expected to close on June 27, 2025 Eastern Time, subject to customary closing conditions.

FORM 8.3